Latest developments in anticoagulant drug discovery

被引：6
作者：
Broussalis, Erasmia [1 ,2 ,3 ]
Anna, Wallner [2 ]
Trinka, Eugen [3 ]
Mutzenbach, Sebastian [3 ]
Killer, Monika [2 ,3 ]
机构：
[1] Paracelsus Med Univ Salzburg, Christian Doppler Klin, Dept Neuroradiol, A-5020 Salzburg, Austria
[2] Paracelsus Med Univ Salzburg, Christian Doppler Klin, Res Inst Neurointervent, A-5020 Salzburg, Austria
[3] Paracelsus Med Univ Salzburg, Christian Doppler Klin, Dept Neurol, A-5020 Salzburg, Austria
来源：
DRUG DISCOVERY TODAY | 2014年 / 19卷 / 07期
关键词：
FACTOR-XA INHIBITOR; ORAL DIRECT THROMBIN; NONVALVULAR ATRIAL-FIBRILLATION; TOTAL KNEE REPLACEMENT; ACUTE CORONARY SYNDROMES; VENOUS THROMBOEMBOLISM; DOUBLE-BLIND; DABIGATRAN ETEXILATE; STROKE PREVENTION; PHASE-II;
D O I：
10.1016/j.drudis.2014.02.011
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Thromboembolic diseases have increased in number over the past years. Oral anticoagulants impair the formation and progression of thrombotic processes and are therefore of great importance in the treatment of these diseases. Until recently, vitamin K antagonists were used to block the coagulation system. But these agents display a lot of interactions besides their narrow therapeutic range and have potential risk of hemorrhage complications. Therefore, other factors of the coagulation cascade are currently being explored as therapeutic targets for the development of novel anticoagulants. This review will provide an overview of new drugs promising more effectiveness in the treatment of arterial and venous embolism. Furthermore, pharmacodynamics and drug interactions regarding new anticoagulants will be reported.
引用
收藏
页码：921 / 935
页数：15
相关论文
共 110 条
  • [11] What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
    Ahrens, Ingo
    Lip, Gregory Y. H.
    Peter, Karlheinz
    [J]. THROMBOSIS AND HAEMOSTASIS, 2011, 105 (04) : 574 - 578
  • [12] Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
    Alexander, John H.
    Lopes, Renato D.
    James, Stefan
    Kilaru, Rakhi
    He, Yaohua
    Mohan, Puneet
    Bhatt, Deepak L.
    Goodman, Shaun
    Verheugt, Freek W.
    Flather, Marcus
    Huber, Kurt
    Liaw, Danny
    Husted, Steen E.
    Lopez-Sendon, Jose
    De Caterina, Raffaele
    Jansky, Petr
    Darius, Harald
    Vinereanu, Dragos
    Cornel, Jan H.
    Cools, Frank
    Atar, Dan
    Luis Leiva-Pons, Jose
    Keltai, Matyas
    Ogawa, Hisao
    Pais, Prem
    Parkhomenko, Alexander
    Ruzyllo, Witold
    Diaz, Rafael
    White, Harvey
    Ruda, Mikhail
    Geraldes, Margarida
    Lawrence, Jack
    Harrington, Robert A.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08) : 699 - 708
  • [13] Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
    Alexander, John H.
    Becker, Richard C.
    Bhatt, Deepak L.
    Cools, Frank
    Crea, Filippo
    Dellborg, Mikael
    Fox, Keith A. A.
    Goodman, Shaun G.
    Harrington, Robert A.
    Huber, Kurt
    Husted, Steen
    Lewis, Basil S.
    Lopez-Sendon, Jose
    Mohan, Puneet
    Montalescot, Gilles
    Ruda, Mikhail
    Ruzyllo, Witold
    Verheugt, Freek
    Wallentin, Lars
    Darius, Harald
    Simoons, Maarten
    Boersma, Eric
    DeLemos, James
    Spencer, Fred
    [J]. CIRCULATION, 2009, 119 (22) : 2877 - U39
  • [14] [Anonymous], BMJ
  • [15] Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents
    Bassand, Jean-Pierre
    [J]. EUROPACE, 2012, 14 (03): : 312 - 324
  • [16] Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
    Bauersachs, Rupert
    Berkowitz, Scott D.
    Brenner, Benjamin
    Buller, Harry R.
    Decousus, Herve
    Gallus, Alex S.
    Lensing, Anthonie W.
    Misselwitz, Frank
    Prins, Martin H.
    Raskob, Gary E.
    Segers, Annelise
    Verhamme, Peter
    Wells, Phil
    Agnelli, Giancarlo
    Bounameaux, Henri
    Cohen, Alexander
    Davidson, Bruce L.
    Piovella, Franco
    Schellong, Sebastian
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) : 2499 - 2510
  • [17] Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran
    Beasley, B. Nhi
    Unger, Ellis F.
    Temple, Robert
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1788 - 1790
  • [18] Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
    Buller, Harry R.
    Prins, Martin H.
    Lensing, Anthonie W. A.
    Decousus, Herve
    Jacobson, Barry F.
    Minar, Erich
    Chlumsky, Jaromir
    Verhamme, Peter
    Wells, Phil
    Agnelli, Giancarlo
    Cohen, Alexander
    Berkowitz, Scott D.
    Bounameaux, Henri
    Davidson, Bruce L.
    Misselwitz, Frank
    Gallus, Alex S.
    Raskob, Gary E.
    Schellong, Sebastian
    Segers, Annelise
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (14) : 1287 - 1297
  • [19] Antithrombotic Therapy in Cardiac Embolism
    Cervera, Alvaro
    Chamorro, Angel
    [J]. CURRENT CARDIOLOGY REVIEWS, 2010, 6 (03) : 227 - 237
  • [20] Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF
    Cleland, John G. F.
    Coletta, Alison P.
    Torabi, Azam
    Clark, Andrew L.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (08) : 802 - 805
12345678910